in many cases Big Pharma enter as a partner with a condition upon positive results of either a licensing agreement or a milestone acquisition.
Another Biotech today announced they are penning a licensing agreement that stock has climbed 35% today,
Big Pharma have to walk a fine line , they need empirical evidence to invest their own SH/Funds but are aware that the same positive data will drive up the SP so taking an equity position early with some hurt money ,eg$20m gives them first right of refusal , this also signals to other Big Pharma they have a foot in the door and have established a commercial relationship
As SH we want the MC of our company SNT to be as high as possible before BP come knocking , Takeovers are at multiples of the MC,,
Phase III can be wholly carried out by Big Pharma they, lately some hugely significant T/O have occurred upon positive phase II data ,,
Best of luck with your investments,, NZT
- Forums
- ASX - By Stock
- Ann: Presentation: Phase 2 study of SNT-5505 in myelofibrosis
SNT
syntara limited
Add to My Watchlist
1.72%
!
5.7¢

in many cases Big Pharma enter as a partner with a condition...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
5.7¢ |
Change
-0.001(1.72%) |
Mkt cap ! $91.81M |
Open | High | Low | Value | Volume |
5.8¢ | 5.9¢ | 5.6¢ | $103.6K | 1.816M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 18349 | 5.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.8¢ | 352957 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 634121 | 0.056 |
3 | 63455 | 0.055 |
3 | 60410 | 0.054 |
4 | 394430 | 0.053 |
3 | 172230 | 0.052 |
Price($) | Vol. | No. |
---|---|---|
0.058 | 352957 | 3 |
0.059 | 506403 | 2 |
0.060 | 106924 | 2 |
0.061 | 150000 | 1 |
0.062 | 170627 | 3 |
Last trade - 13.03pm 18/06/2025 (20 minute delay) ? |
Featured News
SNT (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
SPONSORED BY The Market Online